Justfaro 300 Tablet ER contains Faropenem 300 mg, a broad-spectrum oral carbapenem antibiotic indicated for the treatment of various bacterial infections. Faropenem exhibits bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell lysis and death. This extended-release formulation ensures sustained plasma concentrations, enhancing therapeutic efficacy and improving patient compliance by reducing dosing frequency. Justfaro 300 Tablet ER is effective against a wide range of gram-positive and gram-negative aerobic and anaerobic pathogens, making it suitable for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections. It is particularly useful in cases where resistance to other beta-lactam antibiotics is a concern. The drug should be administered as prescribed by a healthcare professional, with dosage adjustments considered in patients with renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain, which are generally mild and transient. Hypersensitivity reactions are rare but warrant immediate discontinuation and medical attention. Justfaro 300 Tablet ER should be used cautiously in patients with a history of beta-lactam allergy. Proper adherence to the prescribed regimen is essential to prevent the development of antibiotic resistance.